| Univariate RR | Multivariate RR* | |
| Sex | ||
| Males | 1.10 (0.86 to 1.41) | 1.07 (0.83 to 1.39) |
| Females | 1.0 (reference) | 1.0 (reference) |
| Age at treatment start | ||
| Q1 (<46) | 1.0 (reference) | 1.0 (reference) |
| Q2 (46–55) | 1.29 (0.89 to 1.87) | 1.30 (0.89 to 1.89) |
| Q3 (56–63) | 1.75 (1.21 to 2.50) | 1.51 (1.05 to 2.19) |
| Q4 (>64) | 3.04 (2.17 to 4.26) | 2.12 (1.48 to 3.04) |
| RA duration at treatment start | ||
| Missing | 1.42 (0.96 to 2.10) | 1.29 (0.87 to 1.92) |
| Q1 (<4) | 1.0 (reference) | 1.0 (reference) |
| Q2 (4–9) | 1.50 (0.97 to 2.31) | 1.43 (0.93 to 2.23) |
| Q3 (10–17) | 1.69 (1.10 to 2.59) | 1.41 (0.92 to 2.22) |
| Q4 (<17) | 1.96 (1.31 to 2.98) | 1.41 (0.92 to 2.15) |
| DAS28 at treatment start | ||
| Missing | 1.35 (0.95 to 1.93) | 1.06 (0.65 to 1.72) |
| Q1 (<4.86) | 1.0 (reference) | 1.0 (reference) |
| Q2 (4.86–5.71) | 1.15 (0.79 to 1.70) | 1.04 (0.70 to 1.54) |
| Q3 (5.71–6.53) | 1.21 (0.83 to 1.78) | 0.87 (0.58 to 1.29) |
| Q4 (>6.53) | 1.19 (0.81 to 1.73) | 0.76 (0.51 to 1.14) |
| HAQ at treatment start | ||
| Missing | 1.88 (1.28 to 2.74) | 1.28 (0.73 to 2.25) |
| Q1(<1.00) | 1.0 (reference) | 1.0 (reference) |
| Q2 (1.00–1.49) | 1.35 (0.89 to 2.04) | 1.30 (0.86 to 1.98) |
| Q3 (1.50–1.88) | 1.81 (1.21 to 2.72) | 1.47 (0.96 to 2.27) |
| Q4 (>1.88) | 2.49 (1.73 to 3.57) | 1.86 (1.23 to 2.80) |
| DMARD at treatment start | ||
| Missing | 1.00 (0.70 to 1.44) | 1.24 (0.60 to 2.57) |
| No DMARD | 1.00 (reference) | 1.00 (reference) |
| MTX | 0.72 (0.54 to 0.94) | 0.91 (0.69 to 1.20) |
| Other DMARDs | 1.50 (1.04 to 2.17) | 1.45 (1.00 to 2.12) |
| Steroids at treatment start | ||
| Missing | 1.10 (0.79 to 1.53) | 0.76 (0.41 to 1.42) |
| No | 1.0 (reference) | 1.0 (reference) |
| Yes | 1.07 (0.83 to 1.39) | 0.90 (0.69 to 1.17) |
| Co-morbidity at treatment start | ||
| COPD | 2.43 (1.56 to 3.79) | 1.52 (0.96 to 2.42) |
| Diabetes | 2.07 (1.37 to 3.10) | 1.43 (0.94 to 2.18) |
| Any CVD | 2.41 (1.91 to 3.05) | 1.61 (1.24 to 2.07) |
| Infection | 2.07 (1.65 to 2.58) | 1.63 (1.28 to 2.07) |
COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; DAS28, Disease Activity Score 28; DMARD, disease-modifying anti-rheumatic drug; HAQ, Health Assessment Questionnaire; MTX, methotrexate.
RRs estimated through Poisson regression. Continuous variables are categorised into quartiles (Q1–Q4).
*Adjusted for all parameters in the table